{"id":1782,"date":"2022-11-22T13:47:00","date_gmt":"2022-11-22T12:47:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1782"},"modified":"2024-03-30T13:48:07","modified_gmt":"2024-03-30T12:48:07","slug":"11-liecivo-abrocitinib-cibinqo-na-liecbu-stredne-tazkej-a-tazkej-atopickej-dermatitidy-u-dospelych","status":"publish","type":"post","link":"https:\/\/www.niho.sk\/en\/11-liecivo-abrocitinib-cibinqo-na-liecbu-stredne-tazkej-a-tazkej-atopickej-dermatitidy-u-dospelych\/","title":{"rendered":"11: Lie\u010divo abrocitinib (Cibinqo) na lie\u010dbu stredne \u0165a\u017ekej a \u0165a\u017ekej atopickej dermatit\u00eddy u dospel\u00fdch"},"content":{"rendered":"
    \n
  1. Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n

    Atopick\u00e1 dermatit\u00edda, tie\u017e zn\u00e1ma ako atopick\u00fd ekz\u00e9m, je chronick\u00e9 z\u00e1palov\u00e9 ko\u017en\u00e9 ochorenie, sprev\u00e1dzan\u00e9 naj\u010dastej\u0161ie za\u010dervenan\u00edm, suchos\u0165ou poko\u017eky a svrben\u00edm. Poru\u0161en\u00e1 bari\u00e9ra ko\u017ee je navy\u0161e rizikom pre vznik infekci\u00ed. Ide o epizodick\u00e9 ochorenie, \u010do znamen\u00e1, \u017ee sa striedaj\u00fa obdobia vzplanutia (zhor\u0161enia pr\u00edznakov) a remisie (\u00fastupu pr\u00edznakov). Zvy\u010dajne nastupuje v detskom veku a u pribli\u017ene polovice pacientov pretrv\u00e1va do dospelosti.<\/p>\n\n\n\n

    Svrbenie, ktor\u00e9 ochorenie sprev\u00e1dza, je \u010dasto zhor\u0161en\u00e9 v noci. To vedie k nespavosti, zn\u00ed\u017eenej kvalite \u017eivota a predstavuje z\u00e1\u0165a\u017e pre pacienta aj jeho bl\u00edzkych. Atopick\u00e1 dermatit\u00edda je spojen\u00e1 s vy\u0161\u0161ou mieru depres\u00edvnych pr\u00edhod pacientov, \u00fazkosti, rodi\u010dovskej depresie, u\u017e\u00edvania antidepres\u00edv a rizika samovr\u00e1\u017ed. Pacientov za\u0165a\u017euj\u00fa aj proced\u00fary starostlivosti o ko\u017eu, ktor\u00e9 vy\u017eaduj\u00fa pravidelnos\u0165 a m\u00f4\u017eu by\u0165 finan\u010dne a \u010dasovo n\u00e1ro\u010dn\u00e9. <\/p>\n\n\n\n

      \n
    1. O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n

      Liek Cibinqo obsahuje lie\u010divo abrocitinib. Abrocitinib patr\u00ed do skupiny liekov naz\u00fdvan\u00fdch inhib\u00edtory Janusov\u00fdch kin\u00e1z, ktor\u00e9 pom\u00e1haj\u00fa zni\u017eova\u0165 z\u00e1pal. Prostredn\u00edctvom zni\u017eovania aktivity enz\u00fdmov Janusovej kin\u00e1zy m\u00e1 Cibinqo zmier\u0148ova\u0165 svrbenie a\u00a0z\u00e1pal ko\u017ee pri atopickom ekz\u00e9me.<\/p>\n\n\n\n

      Abrocitinib (Cibinqo) v kombin\u00e1cii so \u0161tandardnou terapiou dosiahol \u0161tatisticky v\u00fdznamn\u00e9 zlep\u0161enie v ukazovate\u013eoch hodnotiacich rozsah a z\u00e1va\u017enos\u0165 ekz\u00e9mu a svrbenie oproti samotnej \u0161tandardnej terapii. Z poh\u013eadu bezpe\u010dnosti je terapia abrocitinibom dobre zvl\u00e1dnute\u013en\u00e1 a v\u00fdskyt z\u00e1va\u017en\u00fdch ne\u017eiad\u00facich udalost\u00ed je n\u00edzky.<\/p>\n\n\n\n

      Cibinqo sa pod\u00e1va \u00fastne vo forme tabliet v za\u010diato\u010dnej d\u00e1vke 200 mg jedenkr\u00e1t denne.<\/p>\n\n\n\n

      Liek Cibinqo s lie\u010divom abrocitinib bol registrovan\u00fd Eur\u00f3pskou liekovou agent\u00farou v decembri 2021.<\/p>\n\n\n\n

        \n
      1. Ako sa na abrocitinib pozeraj\u00fa odborn\u00edci? <\/strong><\/li>\n<\/ol>\n\n\n\n

        Odborn\u00edci, ktor\u00fdch oslovilo NIHO sa zhodli, \u017ee na lie\u010dbu bud\u00fa vhodn\u00ed takmer v\u0161etci pacienti s \u0165a\u017ekou a \u010das\u0165 pacientov so stredne \u0165a\u017ekou atopickou dermatit\u00eddou. Jeden odborn\u00edk odhadol po\u010det vhodn\u00fdch pacientov na Slovensku na pribli\u017ene 7000.<\/p>\n\n\n\n

        Odborn\u00edci o\u010dak\u00e1vaj\u00fa v\u00fdznamn\u00fd klinick\u00fd pr\u00ednos technol\u00f3gie, najm\u00e4 v d\u00e1vke 200 mg\/de\u0148. O\u010dak\u00e1vaj\u00fa pr\u00ednos v porovnan\u00ed s cyklospor\u00ednom, r\u00fdchly n\u00e1stup \u00fa\u010dinku a dlhodob\u00e9 pretrv\u00e1vanie dosiahnut\u00fdch odpoved\u00ed. Pr\u00ednos vidia aj v mo\u017enosti monoterapie, bez potreby \u010fal\u0161ej sprievodnej lie\u010dby.<\/p>\n\n\n\n

          \n
        1. \u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n

          Dr\u017eite\u013e registr\u00e1cie (Pfizer Europe) navrhuje, aby hraden\u00fa lie\u010dbu mohol indikova\u0165 dermatovenerol\u00f3g alebo alergol\u00f3g u pacientov so stredne \u0165a\u017ekou a\u017e \u0165a\u017ekou atopickou dermatit\u00eddou, ktor\u00ed s\u00fa kandid\u00e1tmi na syst\u00e9mov\u00fa lie\u010dbu.<\/p>\n\n\n\n

          \u017diadate\u013e navrhuje ofici\u00e1lnu maxim\u00e1lnu cenu vo verejnej lek\u00e1rni a pln\u00fa \u00fahradu na \u00farovni 1 204,52 eur za balenie Cibinqo 100 mg, tbl flm 28 x 100 mg a 1342,59 eur za balenie Cibinqo 200 mg, tbl flm 28 x 200 mg. <\/p>\n\n\n\n

          NIHO odpor\u00fa\u010da nevyhovie\u0165 <\/strong>\u017eiadosti o kategorizovanie lieku Cibinqo, pokia\u013e:<\/p>\n\n\n\n

            \n
          • ned\u00f4jde k \u00faprave podmienok hradenia na z\u00e1klade odporu\u010dan\u00ed NIHO<\/li>\n\n\n\n
          • a z\u00e1rove\u0148 dr\u017eite\u013e registr\u00e1cie neposkytne z\u013eavu vo v\u00fd\u0161ke, ktor\u00fa navrhuje NIHO, aby boli splnen\u00e9 krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti. <\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"

            NIHO odpor\u00fa\u010da nevyhovie\u0165 \u017eiadosti o kategorizovanie lieku Cibinqo, pokia\u013e…<\/p>","protected":false},"author":3,"featured_media":1783,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[59,58],"class_list":["post-1782","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-abrocitinib","tag-cibinqo"],"_links":{"self":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1782"}],"version-history":[{"count":0,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media\/1783"}],"wp:attachment":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}